Literature DB >> 17937919

Structural basis of EZH2 recognition by EED.

Zhifu Han1, Xinmiao Xing, Min Hu, Yin Zhang, Peiyuan Liu, Jijie Chai.   

Abstract

The WD-repeat domain is a highly conserved recognition module in eukaryotes involved in diverse cellular processes. It is still not well understood how the bottom of a WD-repeat domain recognizes its binding partners. The WD-repeat-containing protein EED is one component of the PRC2 complex that possesses histone methyltransferase activity required for gene repression. Here we report the crystal structure of EED in complex with a 30 residue peptide from EZH2. The structure reveals that the peptide binds to the bottom of the WD-repeat domain of EED. The structural determinants of EZH2-EED interaction are present not only in EZH2 and EZH1 but also in its Drosophila homolog E(Z), suggesting that the recognition of ESC by E(Z) in Drosophila employs similar structural motifs. Structure-based mutagenesis identified critical residues from both EED and EZH2 for their interaction. The structure presented here may provide a template for understanding of how WD-repeat proteins recognize their interacting proteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17937919     DOI: 10.1016/j.str.2007.08.007

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  60 in total

1.  Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2).

Authors:  Chao Xu; Chuanbing Bian; Wei Yang; Marek Galka; Hui Ouyang; Chen Chen; Wei Qiu; Huadong Liu; Amanda E Jones; Farrell MacKenzie; Patricia Pan; Shawn Shun-Cheng Li; Hengbin Wang; Jinrong Min
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

Review 2.  Polycomb and the emerging epigenetics of pancreatic cancer.

Authors:  Adrienne Grzenda; Tamas Ordog; Raul Urrutia
Journal:  J Gastrointest Cancer       Date:  2011-06

Review 3.  Mechanisms of polycomb gene silencing: knowns and unknowns.

Authors:  Jeffrey A Simon; Robert E Kingston
Journal:  Nat Rev Mol Cell Biol       Date:  2009-09-09       Impact factor: 94.444

Review 4.  Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.

Authors:  Daphné Dupéré-Richer; Jonathan D Licht
Journal:  Curr Opin Hematol       Date:  2017-07       Impact factor: 3.284

5.  First critical repressive H3K27me3 marks in embryonic stem cells identified using designed protein inhibitor.

Authors:  James D Moody; Shiri Levy; Julie Mathieu; Yalan Xing; Woojin Kim; Cheng Dong; Wolfram Tempel; Aaron M Robitaille; Luke T Dang; Amy Ferreccio; Damien Detraux; Sonia Sidhu; Licheng Zhu; Lauren Carter; Chao Xu; Cristina Valensisi; Yuliang Wang; R David Hawkins; Jinrong Min; Randall T Moon; Stuart H Orkin; David Baker; Hannele Ruohola-Baker
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-01       Impact factor: 11.205

Review 6.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

7.  EED-associated overgrowth in a second male patient.

Authors:  Ana Sa Cohen; William T Gibson
Journal:  J Hum Genet       Date:  2016-05-19       Impact factor: 3.172

8.  Novel HIV-1 knockdown targets identified by an enriched kinases/phosphatases shRNA library using a long-term iterative screen in Jurkat T-cells.

Authors:  Sylvie Rato; Sara Maia; Paula M Brito; Leonor Resende; Carina F Pereira; Catarina Moita; Rui P Freitas; José Moniz-Pereira; Nir Hacohen; Luis Ferreira Moita; Joao Goncalves
Journal:  PLoS One       Date:  2010-02-17       Impact factor: 3.240

9.  Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors.

Authors:  Mao-Rong Zhu; Dao-Hai Du; Jun-Chi Hu; Lian-Chun Li; Jing-Qiu Liu; Hong Ding; Xiang-Qian Kong; Hua-Liang Jiang; Kai-Xian Chen; Cheng Luo
Journal:  Acta Pharmacol Sin       Date:  2017-08-31       Impact factor: 6.150

Review 10.  H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.

Authors:  J N Nichol; D Dupéré-Richer; T Ezponda; J D Licht; W H Miller
Journal:  Adv Cancer Res       Date:  2016-06-17       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.